ANAB241220C35000
- 3.75
- 0.000.00%
AnaptysBio Newsroom
AnaptysBio, Inc.'s (NASDAQ:ANAB) 45% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
Broker Revenue Forecasts For AnaptysBio, Inc. (NASDAQ:ANAB) Are Surging Higher
AnaptysBio Is Maintained at Overweight by JP Morgan
Is AnaptysBio (NASDAQ:ANAB) Using Debt In A Risky Way?
J.P. Morgan Maintains AnaptysBio(ANAB.US) With Buy Rating, Announces Target Price $66
AnaptysBio Price Target Lowered to $66 From $75 at JPMorgan
Truist Financial Maintains AnaptysBio(ANAB.US) With Hold Rating
Analysts Offer Insights on Healthcare Companies: Autolus Therapeutics (AUTL), Molina Healthcare (MOH) and AnaptysBio (ANAB)
Guggenheim Maintains AnaptysBio(ANAB.US) With Buy Rating
Stifel Maintains AnaptysBio(ANAB.US) With Buy Rating, Announces Target Price $59
Analysts Are Bullish on Top Healthcare Stocks: AnaptysBio (ANAB), Outset Medical (OM)
Wells Fargo Maintains AnaptysBio(ANAB.US) With Buy Rating, Maintains Target Price $56
Express News | HC Wainwright & Co. Maintains Buy on AnaptysBio, Lowers Price Target to $52
AnaptysBio Analyst Ratings
Piper Sandler Maintains AnaptysBio(ANAB.US) With Buy Rating, Maintains Target Price $80
TD Cowen Maintains AnaptysBio(ANAB.US) With Buy Rating
A Quick Look at Today's Ratings for AnaptysBio(ANAB.US), With a Forecast Between $45 to $80
Analysts Conflicted on These Healthcare Names: AnaptysBio (ANAB), Stoke Therapeutics (STOK) and Immatics (IMTX)
AnaptysBio: Promising Pipeline and Strong Cash Reserves Underscore Buy Rating Despite Recent Stock Decline
Promising Pipeline Developments Position AnaptysBio as a Buy: Focus on ANB032 and Rosnilimab